Trials & Filings

Halozyme Gets PFS, OS Results for PEGPH20

Stage IV metastatic pancreatic cancer treatment to move to Phase II

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Halozyme Therapeutics posted data from its Phase Ib trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer. The data indicate mature patient progression free survival (PFS) and ongoing overall survival (OS), suggesting a potential clinical benefit of using PEGPH20 with gemcitabine in patients with high levels of tumor associated hyaluronan (HA). In this single-arm study, all patients r...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters